GMV’s intraoperative radiation therapy planner breaks into the Polish market
GMV’s inhouse development radiance, unique in the world, has received FDA authorization and CE mark approval for health products
Adoption of the intraoperative radiotherapy player fits in perfectly with the country’s legislation, which calls for a previous dosimetry study and also a record of the patient dose distribution, something only radiance can guarantee
This development places Poland in the technological vanguard and makes it a role model for other countries
Bydgoszcz Oncology Center and Warsaw’s Maria Skłodowska-Curie Institute of Oncology have become Poland’s first two hospitals to purchase radiance, GMV’s intraoperative radiation therapy (IORT) planner. The transactions were negotiated through Candela Ltd and RTA, respectively, in both cases under non-exclusive distribution contracts with GMV.
radiance, developed by GMV, is the world’s only product for planning intraoperative radiation therapy and ensuring that the whole process is repeatable. This planning system has proven to be a boon for IORT professionals, allowing them to carry out the whole procedure more reliably in all its protocol phases. radiance is the perfect simulation and planning instrument for radiation oncologists, surgeons, physicists and other IORT professionals.
Bydgoszcz Oncology Center, founded in 1990, is one of Europe’s most advanced cancer treatment centers, boasting the most groundbreaking technologies and medical solutions. These innovations include both therapy and diagnosis methods to build towards customized therapy.
Warsaw’s Maria Skłodowska-Curie Institute of Oncology, for its part, was founded in 1932 by Maria Skłodowska-Curie in collaboration with the Polish government. Today it is a specialized health institute of the Polish Ministry of Health. Also running regional branches in Gliwice and Krakow, it is Poland’s leading and most specialized cancer research and treatment center.
Poland’s radiation-therapy legislation calls for a previous radiation dosimetry study before going ahead with any radiotherapy treatment and also for recording of the patient dose distribution. radiance ensures that these two requisites are met in the best way possible since it is the only system that can guarantee the reliability of these readings according to the specialist international radiation therapy groups (AAPM Task Group 72 and Task Force 48).
The purchase of the intraoperative radiotherapy planner by these two hospitals is a landmark development in the European spread of radiance. Collaboration with two such prestigious European institutions as the Bydgoszcz Oncology Center and Warsaw’s Maria Skłodowska-Curie Institute of Oncology boosts GMV’s standing within the health sector in general and oncology in particular.
These two installations place Poland in the technological vanguard of intraoperative radiation therapy and make it a role model for other countries in term of implementing a repeatable, plannable and recordable procedure meeting the strictest international recommendations.
radiance enables the radiation dose and distribution to be planned beforehand, as well as other critical treatment parameters for each specific patient. radiance has been developed by GMV, leader in the development and application of innovation and advanced technologies, in collaboration with the research group of Gregorio Marañón General University Hospital and a group of prestigious Spanish universities and hospitals. It enables surgeons to make a complete pre-surgery analysis and decide on the best treatment for each particular patient.
The technological complexity of this and other GMV developments calls for various quality standards in its processes. For this reason GMV’s intraoperative radiation therapy planner has obtained CE Mark approval and authorization from the USA’s Food and Drug Administration, paving the way for the marketing of radiance in the USA.